Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • International Immunopharmacology br investigated in

    2020-08-03

     International Immunopharmacology 70 (2019) 241–251
    investigated in the future.
    In conclusion, the present study demonstrated the HELT con-stituents of bufadienolides exhibited high antitumor activity against three kinds of cancer EPZ031686 and low toxicity to CIK cells. Moreover, we verified the effects of HELT constituent F18 on activating hematopoietic function, stimulating proliferation of the spleen and NK cells, and promoting the secretion of IFN-γ and IgG1 in a lymphatic metastatic model. These findings provide an experimental basis for clinical ap-plication of HELT bufadienolides in lymphatic chemotherapy.
    Competing interests
    The authors declared no conflicts of interests.
    Acknowledgements
    Funding
    This work was supported by the National Natural Science Foundation of China, China (grant no. 81871317) and Beijing Lanhai Kangfu Medical Technology Research Co. Ltd.
    Author contribution
    Yingxin Xu, Shaoyou Xia and Xiaohui Du put forward the idea and designed the study. Zhenyu Zou, Shidong Hu, Zilong Hu and Yuxuan Li performed the experiments. Songyan Li, Hongliang Zhang, Yu Yang, Yichen Liu, Xiaolei Xu, Boyan Liu and Yufeng Wang participated in analyzing data. Changzheng He and Xiaowei Xing contributed to drafting the manuscript. All authors reviewed the manuscript.
    References
    I. Bakhutashvili, J. Esparza-Trujillo, S.J. Brancato, J. Karanian, P.K. Agarwal,
    Contents lists available at ScienceDirect
    Sensors and Actuators B: Chemical
    journal homepage: www.elsevier.com/locate/snb
    Application of NiFe2O4 nanotubes as catalytically promoted sensing
    platform for ratiometric electrochemiluminescence analysis of ovarian T
    cancer marker
    Jiani Wang a,1, Jianrong Songb,1, Hongli Zhenga,c, Xiangqin Zhengb,a, , Hong Daia,b,c, , Zhensheng Hongc, Yanyu Linc a Fujian Provincial Key Laboratory of Advanced Materials Oriented Chemical Engineering, Fujian Normal University, Fuzhou, Fujian, 350108, China b Fujian Provincial Maternity and Children`s Hospital, Affiliated hospital of Fujian Medical University, Fuzhou, Fujian, 350108, China c College of Chemistry and Material & College of Physics and Energy Fujian Normal University, Fuzhou, Fujian, 350108, China
    Keywords:
    Ratiometric ECL biosensor
    NiFe2O4 nanotubes
    Oxygen evolution reaction
    Human epididymis protein 4 (HE4) 
    Herein, a delicate ratiometric electrochemiluminescence biosensor was designed for the detection of human epididymis protein 4 (HE4) based on 2-(Dibutylamino)ethanol (DBAE) and lucigenin as anodic and cathodic ECL emitter, respectively. Initially, NiFe2 O4 nanotubes (NiFe2O4 NTs) with charming properties could act as cata-lytically promoted sensing platform. This NiFe2O4 NTs based platform could trigger an intense ECL emission of DBAE for the reason that NiFe2O4 NTs not only achieved the high loading of Envision-Ab1 complex but effec-tively catalyzed the oxygen evolution reaction (OER) to yield oxygen. Moreover, the Envision complex, a polymeric material containing enrich horseradish peroxidase (HRP) could further accelerate the H2O2 decom-position to generate superoxide (O2%−) for the enhancement of the ECL emission process of two luminophors. It’s noteworthy that hexagonal boron nitride nanosheets (h-BN) as the nanolabels, was first illustrated to be capable of immobilizing a large quantity of lucigenin and retaining intense and stable ECL emission of lucigenin in the alkaline condition. Benefiting from the above merits, a new ECL ratiometric sensing mode was established for the sensitive determination of HE4 in a range from 10 fg/mL to 10 ng/mL with the detection limit of 3.3 fg/mL. The strategy exhibited broad prospect in early ovarian cancer diagnosis and blazed a new path for other tumors screening.
    1. Introduction
    Recent years, ovarian cancer has come into notice worldwide for its highest mortality of all gynecologic malignancies. Concretely, more than 20,000 ovarian cancer cases occur and causes about 140,000 deaths in females every year. [1,2] As most of the ovarian cancer pa-tients are diagnosed at advanced stages of III and IV for the lack of specific symptoms, the 5-year survival rate was low to 30% [3,4]. So screening ovarian cancer at the early stage will effectively improve the survival rate. Up to now, the typical biomarkers including cancer an-tigen 125 (CA125) and human epididymis protein 4 (HE4) have been commonly used for the early ovarian cancer diagnosis [5]. However, the sensitivity and specificity utilizing CA125 as biomarker for ovarian cancer diagnosis was limited because the level of CA125 was usually elevated in benign gynecologic conditions [6]. In contrast, HE4 has
    been considered to be a more promising biomarker for early stage de-tection owing to its less increase in benign tumors [7]. Therefore, de-veloping an effective technique for the sensitive determination of HE4 was of vital importance.